{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:22:41Z","timestamp":1790011361324,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K08889"],"award-info":[{"award-number":["21K08889"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K09168"],"award-info":[{"award-number":["20K09168"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s10637-023-01337-8","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T07:53:25Z","timestamp":1676620405000},"page":"183-192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cyclin-dependent kinase (CDK) 4\/6 inhibition in non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations"],"prefix":"10.1007","volume":"41","author":[{"given":"Atsushi","family":"Osoegawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Takumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Nakatsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Karashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiyo","family":"Miyawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Sugio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"1337_CR1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","volume":"144","author":"J Ferlay","year":"2019","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, Znaor A, Bray F (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144:1941\u20131953. https:\/\/doi.org\/10.1002\/ijc.31937","journal-title":"Int J Cancer"},{"key":"1337_CR2","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3978\/j.issn.2218-6751.2014.11.11","volume":"4","author":"T Kohno","year":"2015","unstructured":"Kohno T, Nakaoku T, Tsuta K, Tsuchihara K, Matsumoto S, Yoh K, Goto K (2015) Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res 4:156\u2013164. https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2014.11.11","journal-title":"Transl Lung Cancer Res"},{"key":"1337_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS, Investigators F (2018) Osimertinib in untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 378:113\u2013125. https:\/\/doi.org\/10.1056\/NEJMoa1713137","journal-title":"N Engl J Med"},{"key":"1337_CR4","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Dieras V, Slamon DJ (2016) Palbociclib and Letrozole in Advanced breast Cancer. N Engl J Med 375:1925\u20131936. https:\/\/doi.org\/10.1056\/NEJMoa1607303","journal-title":"N Engl J Med"},{"key":"1337_CR5","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Tredan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A (2017) MONARCH 3: Abemaciclib as initial therapy for advanced breast Cancer. J Clin Oncol 35:3638\u20133646. https:\/\/doi.org\/10.1200\/JCO.2017.75.6155","journal-title":"J Clin Oncol"},{"key":"1337_CR6","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/sj.bjc.6990500","volume":"80","author":"T Mishina","year":"1999","unstructured":"Mishina T, Dosaka-Akita H, Kinoshita I, Hommura F, Morikawa T, Katoh H, Kawakami Y (1999) Cyclin D1 expression in non-small-cell lung cancers: its association with altered p53 expression, cell proliferation and clinical outcome. Br J Cancer 80:1289\u20131295. https:\/\/doi.org\/10.1038\/sj.bjc.6990500","journal-title":"Br J Cancer"},{"key":"1337_CR7","doi-asserted-by":"publisher","first-page":"87044","DOI":"10.18632\/oncotarget.19667","volume":"8","author":"A Osoegawa","year":"2017","unstructured":"Osoegawa A, Gills JJ, Kawabata S, Dennis PA (2017) Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib. Oncotarget 8:87044\u201387053. https:\/\/doi.org\/10.18632\/oncotarget.19667","journal-title":"Oncotarget"},{"key":"1337_CR8","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621\u2013681 58\/3\/621 [pii]. https:\/\/doi.org\/10.1124\/pr.58.3.10","journal-title":"Pharmacol Rev"},{"key":"1337_CR9","first-page":"419","volume":"12","author":"TM Brand","year":"2011","unstructured":"Brand TM, Iida M, Li C, Wheeler DL (2011) The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov Med 12:419\u2013432","journal-title":"Discov Med"},{"key":"1337_CR10","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/ncb0901-802","volume":"3","author":"SY Lin","year":"2001","unstructured":"Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L, Hung MC (2001) Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3:802\u2013808. https:\/\/doi.org\/10.1038\/ncb0901-802","journal-title":"Nat Cell Biol"},{"key":"1337_CR11","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M (2019) Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer 121:725\u2013737. https:\/\/doi.org\/10.1038\/s41416-019-0573-8","journal-title":"Br J Cancer"},{"key":"1337_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2006.09.024","volume":"55","author":"O Gautschi","year":"2007","unstructured":"Gautschi O, Ratschiller D, Gugger M, Betticher DC, Heighway J (2007) Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer 55:1\u201314. https:\/\/doi.org\/10.1016\/j.lungcan.2006.09.024","journal-title":"Lung Cancer"},{"key":"1337_CR13","first-page":"69","volume":"25","author":"J Wang","year":"2006","unstructured":"Wang J, Miao LJ, Wu YM, Wu YJ, Wang XC (2006) [Expression of AKT2, cyclin D1, and MMP-9 and their correlations to clinicopathologic features of non-small cell lung cancer]. Ai Zheng 25:69\u201372","journal-title":"Ai Zheng"},{"key":"1337_CR14","doi-asserted-by":"publisher","first-page":"4165","DOI":"10.1200\/JCO.2004.01.035","volume":"22","author":"A Osoegawa","year":"2004","unstructured":"Osoegawa A, Yoshino I, Tanaka S, Sugio K, Kameyama T, Yamaguchi M, Maehara Y (2004) Regulation of p27 by S-phase kinase-associated protein 2 is associated with aggressiveness in non-small-cell lung cancer. J Clin Oncol 22:4165\u20134173. https:\/\/doi.org\/10.1200\/JCO.2004.01.035","journal-title":"J Clin Oncol"},{"key":"1337_CR15","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","volume":"3","author":"DW Fry","year":"2004","unstructured":"Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL (2004) Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3:1427\u20131438","journal-title":"Mol Cancer Ther"},{"key":"1337_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ccr.2010.05.025","volume":"18","author":"M Puyol","year":"2010","unstructured":"Puyol M, Martin A, Dubus P, Mulero F, Pizcueta P, Khan G, Guerra C, Santamaria D, Barbacid M (2010) A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18:63\u201373. https:\/\/doi.org\/10.1016\/j.ccr.2010.05.025","journal-title":"Cancer Cell"},{"key":"1337_CR17","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.cllc.2021.06.006","volume":"22","author":"HA Yu","year":"2021","unstructured":"Yu HA, Goldberg SB, Le X, Piotrowska Z, Goldman JW, De Langen AJ, Okamoto I, Cho BC, Smith P, Mensi I, Ambrose H, Kraljevic S, Maidment J, Chmielecki J, Li-Sucholeiki X, Doughton G, Patel G, Jewsbury P, Szekeres P, Riess JW (2021) Biomarker-Directed phase II platform study in patients with EGFR sensitizing mutation-positive Advanced\/Metastatic Non-Small Cell Lung Cancer whose disease has progressed on first-line osimertinib therapy (ORCHARD). Clin Lung Cancer 22:601\u2013606. https:\/\/doi.org\/10.1016\/j.cllc.2021.06.006","journal-title":"Clin Lung Cancer"},{"key":"1337_CR18","doi-asserted-by":"publisher","first-page":"100191","DOI":"10.1016\/j.jtocrr.2021.100191","volume":"2","author":"A Osoegawa","year":"2021","unstructured":"Osoegawa A, Yamaguchi M, Nakamura T, Morinaga R, Tanaka K, Kashiwabara K, Miura T, Suetsugu T, Harada T, Asoh T, Taguchi K, Nabeshima K, Kishimoto J, Sakai K, Nishio K, Sugio K (2021) High incidence of C797S mutation in patients with Long Treatment History of EGFR tyrosine kinase inhibitors including Osimertinib. JTO Clin Res Rep 2:100191. https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100191","journal-title":"JTO Clin Res Rep"},{"key":"1337_CR19","doi-asserted-by":"publisher","unstructured":"Cabanos HF, Hata AN (2021) Emerging insights into targeted therapy-tolerant Persister cells in Cancer. Cancers (Basel) 13. https:\/\/doi.org\/10.3390\/cancers13112666","DOI":"10.3390\/cancers13112666"},{"key":"1337_CR20","doi-asserted-by":"publisher","unstructured":"Moore G, Annett S, McClements L, Robson T (2020) Top notch targeting strategies in Cancer: a detailed overview of recent insights and current perspectives. Cells 9. https:\/\/doi.org\/10.3390\/cells9061503","DOI":"10.3390\/cells9061503"},{"key":"1337_CR21","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","volume":"20","author":"K Nakagawa","year":"2019","unstructured":"Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M, Investigators RS (2019) Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20:1655\u20131669. https:\/\/doi.org\/10.1016\/S1470-2045(19)30634-5","journal-title":"Lancet Oncol"},{"key":"1337_CR22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","volume":"20","author":"H Saito","year":"2019","unstructured":"Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M (2019) Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol 20:625\u2013635. https:\/\/doi.org\/10.1016\/S1470-2045(19)30035-X","journal-title":"Lancet Oncol"},{"key":"1337_CR23","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","volume":"15","author":"T Seto","year":"2014","unstructured":"Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, Tajima K, Harada R, Fukuoka M, Yamamoto N (2014) Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 15:1236\u20131244. https:\/\/doi.org\/10.1016\/S1470-2045(14)70381-X","journal-title":"Lancet Oncol"},{"key":"1337_CR24","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2217\/fon-2021-0923","volume":"18","author":"BC Cho","year":"2022","unstructured":"Cho BC, Felip E, Hayashi H, Thomas M, Lu S, Besse B, Sun T, Martinez M, Sethi SN, Shreeve SM, Spira AI (2022) MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. Future Oncol 18:639\u2013647. https:\/\/doi.org\/10.2217\/fon-2021-0923","journal-title":"Future Oncol"},{"key":"1337_CR25","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/2159-8290.CD-14-0326","volume":"4","author":"YY Janjigian","year":"2014","unstructured":"Janjigian YY, Smit EF, Groen HJ, Horn L, Gettinger S, Camidge DR, Riely GJ, Wang B, Fu Y, Chand VK, Miller VA, Pao W (2014) Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov 4:1036\u20131045. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0326","journal-title":"Cancer Discov"},{"key":"1337_CR26","doi-asserted-by":"publisher","first-page":"598265","DOI":"10.3389\/fonc.2021.598265","volume":"11","author":"Q Wu","year":"2021","unstructured":"Wu Q, Luo W, Li W, Wang T, Huang L, Xu F (2021) First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI alone as first-line treatment in Advanced NSCLC with EGFR activating mutation: a systematic review and Meta-analysis of Randomized controlled trials. Front Oncol 11:598265. https:\/\/doi.org\/10.3389\/fonc.2021.598265","journal-title":"Front Oncol"},{"key":"1337_CR27","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/S1470-2045(15)00121-7","volume":"16","author":"JC Soria","year":"2015","unstructured":"Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, Shi X, Webster A, Jiang H, Mok TS (2015) Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol 16:990\u2013998. https:\/\/doi.org\/10.1016\/S1470-2045(15)00121-7","journal-title":"Lancet Oncol"},{"key":"1337_CR28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.cllc.2020.09.023","volume":"22","author":"H Asahina","year":"2021","unstructured":"Asahina H, Tanaka K, Morita S, Maemondo M, Seike M, Okamoto I, Oizumi S, Kagamu H, Takahashi K, Kikuchi T, Isobe T, Sugio K, Kobayashi K (2021) A phase II study of Osimertinib Combined with Platinum Plus Pemetrexed in patients with EGFR-Mutated Advanced Non-Small-cell Lung Cancer: the OPAL Study (NEJ032C\/LOGIK1801). Clin Lung Cancer 22:147\u2013151. https:\/\/doi.org\/10.1016\/j.cllc.2020.09.023","journal-title":"Clin Lung Cancer"},{"key":"1337_CR29","doi-asserted-by":"publisher","first-page":"100271","DOI":"10.1016\/j.esmoop.2021.100271","volume":"6","author":"D Planchard","year":"2021","unstructured":"Planchard D, Feng PH, Karaseva N, Kim SW, Kim TM, Lee CK, Poltoratskiy A, Yanagitani N, Marshall R, Huang X, Howarth P, Janne PA, Kobayashi K (2021) Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced\/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study. ESMO Open 6:100271. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100271","journal-title":"ESMO Open"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01337-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-023-01337-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01337-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T08:07:50Z","timestamp":1682582870000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-023-01337-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1337"],"URL":"https:\/\/doi.org\/10.1007\/s10637-023-01337-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]},"assertion":[{"value":"10 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the internal review board of Oita University Faculty of Medicine (IRB No. 698).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Yohei Takumi, Takafumi Hashimoto, Shotaro Nakatsuji, Mayu Hori, Mayu Sakai, Takashi Karashima, Miyuki Abe, and Michiyo Miyawaki declare they have no financial interests. Atsushi Osoegawa and Kenji Sugio have received speaker and consultant honoraria from AstraZeneca (Cambridge, UK).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial interests"}}]}}